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ABSTRACT 
Probiotics have seen widespread use for a variety of gastrointestinal problems, especially in two common 
disorders:  irritable bowel syndrome and inflammatory bowel disease.  Since a wide variety of probiotic 
preparations has been used, and despite a large number of studies performed, a great deal of heterogeneity 
exists among them.  Straightforward evidence-based recommendations for the use of probiotics in irritable 
bowel syndrome and inflammatory bowel disease have thus been difficult to formulate.  In an effort to improve 
understanding of the risk-benefit balance of probiotics in these conditions, we (1) queried the FAERS database 
for all reported adverse drug events related to probiotics in 2013, and (2) constructed risk-benefit planes for 
both irritable bowel syndrome and inflammatory bowel disease using a geometric approximation of the 
confidence region between risk and benefit.  Our results show that adverse events from probiotics vary widely 
by disease, and when they occur, they are mild and may be difficult to distinguish from the natural history of 
the underlying disorders they are used to treat.  The risk-benefit plane for irritable bowel syndrome straddles 
the risk-benefit threshold, so patients can expect a balance between a low chance of risk and also a low 
chance of benefit.  The risk benefit-plane for inflammatory bowel disease largely lies above the risk-benefit 
threshold, so patients may expect more benefit than risk in most cases.  More standardized and high quality 
research is needed to improve our understanding of risk and benefit for these complex biopharmaceuticals.  
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BACKGROUND 
 
The use of probiotics has substantially increased over the past decade, more than quadrupling from 2007 to 
2012.(1) The World Health Organization defines probiotics as “live organisms which when administered in 
adequate amounts confer a health benefit on the host,”(2), but the term is often used in situations for which no 
health benefit has been proven.  As such, interest has increased in fostering clinical research to add the weight 
of evidence to this unique biopharmaceutical.  If one searches MEDLINE with the term “probiotics”, and results 
are limited to clinical trials, over 1400 clinical studies have been indexed, and more than 1200 of these have 
been performed in the past ten years. Given the heterogeneous and complex nature of probiotics as a drug, 
there is a great deal of heterogeneity in study design(3), and while there are many published trials, only a small 
percentage of them are of high methodological quality.  Perhaps most concerning, however, is that probiotics 
tend to be lumped into a single category, despite representing a diverse group of organisms with wide 
differences in biological effect.(4) Yet even when they are considered separately, since most probiotics are 
regulated as supplements by the United States Food and Drug Administration and other governmental 
agencies worldwide,(5) there is often no guarantee they contain what they say they do.(6) 
 
Naturally, diseases of the gastrointestinal tract are the most commonly studied.  Some of the first disorders 
treated with probiotics have been those thought to be the direct result of an intestinal dysbiosis, or an abnormal 
and harmful fluctuation of intestinal bacterial populations. Most effectively studied has been the prevention of 
antibiotic-associated diarrhea(7, 8) shortening duration of acute infectious diarrhea,(9) and preventing 
recurrent Clostridium difficile infection(10).  In such cases, probiotics tend to have a high benefit-risk ratio, 
mostly owing to relatively low risk,(11) but benefit may also often be low as well, especially with larger, more 
rigorous clinical trials.(7) Given the abovementioned disorders’ association with dysregulation of the human 
microbiome, interest has mounted in the use of probiotics to treat both irritable bowel syndrome (IBS), and 
inflammatory bowel disease (IBD).  While dysbiosis remains a likely,(12-14) but as yet poorly understood 
mechanism for IBD and IBS, this has not stunted the a priori assumption by many clinicians and patients that 
probiotics may be helpful.  
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IBS is a functional gastrointestinal disorder (FGID) that is extraordinarily common throughout the world, 
occurring in roughly 10% of humans from childhood to late adulthood.(15, 16) The FGID clinical guidelines, 
known as the Rome III criteria(17), define IBS as abdominal pain or discomfort occurring at least 3 days per 
month over the preceding 3 months with at least two of the following associated symptoms:  improvement with 
defecation, change in frequency of stool, or change in form or character of stool.  The cause is unknown, 
although a complex etiology with both neurological and intestinal inputs is likely.(18) Therapy typically consists 
of some combination of dietary changes,(19) antispasmodic medications,(20) or other adjunctive 
pharmacotherapy or psychotherapy.(21) Probiotics are frequently tried for IBS, either at the advice of a 
clinician, or over-the-counter by the patient.   
 
Inflammatory bowel disease comes in two general clinical phenotypes:  ulcerative colitis (UC) and Crohn 
disease (CD).  UC results in mucosal inflammation confined to the colon, usually in a contiguous fashion 
beginning in the rectum.  Alternatively, CD can involve any portion of the gastrointestinal tract and can extend 
through the entire intestinal wall.  While their etiologies are unknown, they are both likely related to a 
dysregulated interaction between the normal intestinal microbiota and the host immune system.(12, 13)   
 
Probiotics have been difficult to study(3), largely because they defy typical drug classification in many settings:  
probiotics are complex organisms taken as medications.  As such, existing experience with drug safety and 
efficacy trials may be insufficient to study them.  The assessment of risk and benefit for probiotics is also quite 
complex, since probiotics do not represent a single chemical compound, but a range of diverse live organisms 
with an even wider range of dynamic biological activities.  Pharmacokinetic and pharmacodynamic 
considerations are also challenging to assess,(22) since each microbial population may constitute thousands 
of different active biological molecules.   
 
We seek to provide guidance to clinicians and others caring for patients with IBS and IBD in regards to the risk-
benefit balance for the use of probiotics in these disorders.  We have grouped this guidance into three main 
sections below:   
(1) A summary of the literature describing both risk and benefit of probiotics and IBS and IBD,  
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(2) A description of the adverse drug events (ADEs) for all probiotics in the FDA’s primary reporting service 
(3) A quantitative analysis using a combination of systematic literature search of relevant trials, pooling of 
these existing data and simulation of 5000 patients, and then plotting of these simulated patients on a risk-
benefit plane (RBP) to better visualize what we know about the risk-benefit balance for probiotics in these 
disorders.  
 
 
SUMMARY OF RISKS 
 
A previous systematic review by Didari and colleagues(23) focused on the risk of probiotics across all settings, 
and found that probiotics were generally safe, but found increased risk for immunocompromised patients, 
critically ill patients, and those at the extremes of age.  Probiotics have been studied extensively for a broad 
variety of diseases, including IBS and IBD, yet rigorous assessment of adverse events has only rarely occurred 
in the many clinical trials performed. 
 
IBS 
 
Multiple recent controlled trials designed to assess efficacy have also assessed risk of adverse events, albeit 
heterogeneously. (24-38)  Most trials had no adverse events reported at all.  Most patients who reported ADEs 
reported mild symptoms, most often related to the gastrointestinal tract.  Only three published trials assessed 
ADEs related to probiotics in IBS in any systematic or standardized way.(27, 29, 34)  A recent meta-
analysis(39) showed a pooled relative risk (RR) for an adverse event of any type across all published trials of 
1.21 (95% CI 1.02–1.44) and number needed to harm was 35.  16.5% of patients in all trials had an ADE on 
probiotics, compared with 13.8% of controls.  There were no deaths reported in any trials, and no serious 
adverse events such as cardiovascular or respiratory compromise reported.   
 
IBD 
 
As with IBS, multiple recent IBD trials designed to assess efficacy also addressed safety and ADEs as a 
secondary outcome(40-49).  When these trials were pooled in a recent meta-analysis(50), there was no 
difference in ADEs in patients on probiotics versus controls, with a relative risk of 0.97 (95% CI 0.77-1.19).  No 
trials reported patient deaths during the study period.  Most reported ADEs were gastrointestinal symptoms.  
However, there was significant heterogeneity among trials, and some trials reported a wide confidence interval 
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for relative risk of an ADE.  As with IBS, there was a large degree of heterogeneity among trials in how they 
chose to measure ADEs, and only a single trial appears to have approached this measurement in a systematic 
and comprehensive way.(41) 
 
Special Risk Cases – The Young, the Old, and the Immunosuppressed 
 
Of special concern when introducing a biopharmaceutical containing live bacteria is that patients may develop 
infection from those bacteria due to impaired host immunity.  Three populations are likely to be most affected in 
this scenario:  (1) young children, especially neonates and preterm infants, (2) the elderly, and (3) patients on 
immunosuppressing medications. 
 
Probiotics have been studied extensively in preterm infants in the context of necrotizing enterocolitis (NEC), a 
multifactorial necroinflammatory condition thought to have a basis in the interaction between microbiome and 
host immunity.  These infants may be less likely to develop NEC(51-53), and while concern has long existed 
about probiotic strain-associated sepsis, this risk has not been born out in larger trials.  However, studies 
overall have had mixed results(54, 55).  Infants do not develop IBS, and develop IBD only in extremely rare 
cases, but the apparent safety of probiotics in this group is reassuring that the risk for vulnerable or 
immunocompromised patients may be relatively low.  
 
The elderly represent a large number of patients with IBS and IBD, but the bulk of disease burden remains in 
young and mid-adulthood.  Most clinical trials for IBS or IBD have included some elderly patients, but this 
demographic has been largely unstudied in relation to probiotics.  No trials selected below for quantitative 
analysis specifically listed rates of ADEs in patients greater than 65, and none had large numbers of elderly 
patients enrolled at all.  No publications to our knowledge have specifically addressed the risks related to 
probiotic use in elderly adults for any disease. 
 
Immunocompromised patients are of greatest immediate concern to clinicians prescribing probiotics, since 
many patients with chronic illnesses have IBS and many patients with IBD take immunosuppressants to 
manage the disease.  Many of the trials included in our analysis have demonstrated no added risk to the 
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addition of probiotics when patients are taking immunosuppressants such as thiopurines or biologics, but these 
studies are not designed to effectively determine safety of probiotics in the immunosuppressed host.  A 
MEDLINE search using the terms “lactobacillus,” “bifidobacteria,” “saccharomyces”, “VSL”, or “probiotics” 
combined with “azathioprine,” “mercaptopurine,” “methotrexate,” or “infliximab” did not produce any specific 
publications addressing the risks of probiotic use concurrently with these medicines.  We thus conclude that no 
clear safety data exist to guide clinicians using both immunosuppressants and probiotics simultaneously. 
 
The risk of sepsis from probiotics in all patients, even the immunocompetent, appears to be low, but non-zero.  
The prophylactic administration of probiotics has been associated with increased mortality in septic 
patients(56), so care should be taken before introducing probiotic regimens to severely ill patients.  However, 
sepsis from a probiotic strain such as Lactobacillus remains very unlikely(57), even in at-risk patients. 
 
 
ADVERSE DRUG EVENTS (ADEs) 
 
Probiotics With Reported ADEs 
We queried the United States Food and Drug Administration’s Adverse Drug Event Reporting System 
(FAERS)(58) for the entirety of 2013 and a relational database was built linking reported ADEs with drug 
names.  Drug names associated with probiotic preparations were then isolated from this relational database, 
along with the case’s associated adverse event(s).  Generic terms and genus names (“probiotic”, 
“lactobacillus”, “bifidobacteria”, and “saccharomyces”) and the trade names (Align, Bio-K, Culturelle, 
DanActive, Florajen, Florastor, Kefir, Lactinex, ProBacLac, RepHresh, VSL #3, and Yakult) for popular 
probiotic preparations in the United States were used to find probiotic-related ADEs.  Counts of ADEs by 
probiotic type are shown in Table 1.  These drug names only indicate which drug was reported in FAERS, and 
only show association with an ADE, not causation. 
 
Table 1 – Number of each probiotic (and % of total of 1165 probiotic-associated ADEs) in FAERS in 2013 
 
Probiotic Type Frequency % 
Probiotic 799 68.6% 
Align 132 11.3% 
Lactobacillus 87 7.5% 
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Florastor 65 5.6% 
Culturelle 44 3.8% 
Bifidobacterium 13 1.1% 
Saccharomyces 8 0.7% 
Florajen 6 0.5% 
Lactinex 6 0.5% 
VSL #3 2 0.2% 
Bioflor 1 0.1% 
Kefir 1 0.1% 
Rexell 1 0.1% 
 
 
Types of ADEs 
A total of 2,652,194 ADEs for all drugs were found in the FAERS in 2013.  Among these, 1165 (0.04% of all 
2013 ADEs) were associated with probiotics according to the above search strategy (Table 2), but most ADEs 
only occurred once in a single patient, and there were 420 distinct event types enumerated.  Among probiotics, 
the most commonly reported ADEs were abdominal pain (11% of all ADEs), asthenia (3%), and arthralgia 
(3%).  Two episodes of sepsis (0.2% of all ADEs), eight episodes of colitis (0.8%), and a single episode of 
Crohn disease (0.1% of cases) were reported concurrently with probiotic use.  Data on patients’ other 
medications or medical history are not accessible in FAERS.  In many cases, patients may have had significant 
polypharmacy, and adverse events were reported while taking multiple medications.  These specific ADEs only 
indicate the symptom reported in FAERS, and only show association, not causation. 
 
Table 2 – Most common specific adverse drug events in FAERS.  All events listed in “Other” have 7 or less 
total occurrences.  Some events could have co-occurred with other medications. 
 
Event Frequency % 
Abdominal pain 125 10.7% 
Drug ineffective 39 3.3% 
Arthralgia 34 2.9% 
Asthenia 30 2.6% 
Fatigue 29 2.5% 
Diarrhoea 28 2.4% 
Injection site pain 22 1.9% 
Injection site bruising 16 1.4% 
Anaemia 15 1.3% 
Anxiety 14 1.2% 
Crohn's disease 14 1.2% 
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Alopecia 13 1.1% 
Cough 13 1.1% 
Dizziness 12 1.0% 
Back pain 11 0.9% 
Clostridium difficile infection 11 0.9% 
Flushing 11 0.9% 
Headache 10 0.9% 
Blood pressure increased 9 0.8% 
Dyspnoea 9 0.8% 
Colitis 8 0.7% 
Constipation 8 0.7% 
Contusion 8 0.7% 
Death 8 0.7% 
Incorrect dose administered 8 0.7% 
Injection site erythema 8 0.7% 
Other 646 55.5% 
 
 
 
Therefore, ADEs are quite rare for probiotics (1165 events reported out of more than 2.6 million reported 
events in 2013), despite more than 4 million adults per month reporting taking probiotics.(1)  
 
SUMMARY OF BENEFITS 
 
 
IBS 
 
Overall, current national guidelines are supportive of probiotics,(59) indicating more widespread use by 
gastroenterologists and primary care doctors to treat IBS.  15 trials met our criteria and were used further in the 
quantitative analysis below.(24-38) Overall, results were mixed, but the majority of trials showed some benefit.  
When the results of all published clinical trials were pooled in a recent meta-analysis(39), probiotics were 
effective at improving IBS symptoms, with an OR of 1.27 (95% CI 1.12 – 1.42).  55.8% of patients on probiotics 
had persistent IBS symptoms, compared with 73.1% of patients on placebo.  The trials with the most power 
and best design all tended to have higher ORs of a positive effect (see Table 3).(25-27) 
 
IBD 
 
10 trials met our criteria and were used further in the quantitative analysis below.(40-49) Results were also 
mixed, but a majority of trials showed at least mild benefit of probiotics, more for maintenance of remission 
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than induction of remission (most trials assessed both).  In a recent meta-analysis of all published trials(50), 
the pooled odds ratio of induction of remission was 1.28 (95% CI 1.00-1.41), which favored probiotics.   For 
maintenance of remission, the pooled odds ratio for relapse was 0.73 (95% CI 0.54-0.99), which favored 
probiotics.  However, in both cases, the confidence interval is very close to 1.0, so the significance of either 
result is marginal. 
 
In order to determine the balance between the abovementioned varying degrees of benefit and risk for both 
IBS and IBD, and to account for the heterogeneous distribution of both benefit and risk, we next proceeded to 
a quantitative risk-benefit analysis. 
 
 
 
METHODOLOGY OF QUANTITATIVE RISK-BENEFIT ANALYSIS 
 
Search Strategy  
We identified studies for quantitative analysis by accessing http://www.pubmed.org.  To determine all studies 
using probiotics to treat irritable bowel syndrome, the terms (“probiotic,” “lactobacillus,” “bifidobacteria”, “VSL”, 
or “saccharomyces”) and “irritable bowel syndrome” were used.  Results were limited to studies performed 
through June 30th, 2014, written in English, and entered as clinical trials. To determine all studies using 
probiotics to treat inflammatory bowel disease, the terms (“probiotic,” “lactobacillus,” “bifidobacteria,” “VSL,” or 
“saccharomyces”) and (“inflammatory bowel disease” or “Crohn disease” or “Crohn’s disease” or “ulcerative 
colitis”) were used.  Results were again limited to studies performed through June 30th, 2014, written in 
English with full article text accessible, and entered as clinical trials. The analysis and bibliography of relevant 
published meta-analyses were also queried to find additional studies.  For initial analysis, 77 studies were 
found for IBS and 109 studies for IBD.  The details and results of the search strategy are displayed in Figure 1.    
Each of the studies selected for further quantitative analysis are listed and described in more detail in Table 3.   
In the end, 15 studies were selected for analysis in IBS and 10 studies were selected for IBD. 
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Figure 1 – Search strategy for studies to include in quantitative analysis. 
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Table 3 – Description of studies selected for quantitative analysis.  Benefit is the clinical endpoint for 
the study.  Risk is the likelihood of any ADE (as defined by the study).  
 
Study (Author, Year) # Experimental 
Subjects 
95% C.I. (Benefit) 95% C.I. (Risk) 
Irritable Bowel Syndrome 
Kim 2003 13 0.51 – 1.67 0.96 – 1.04 
Kajander 2005 51 1.12 – 2.44 0.33 – 28.34 
Enck 2008 148 1.52 – 2.56 0.47 – 0.97 
Hong 2009 34 0.68 – 1.85 0.40 – 2.23 
Simren 2010 37 0.85 – 1.61 0.96 – 1.04 
Cha 2012 25 1.14 – 2.56 0.24 – 95.90 
Nobaek 2000 30 0.89 –1.59 0.96 – 1.04 
Niedzielin 2001 20 1.00 – 2.38 0.96 – 1.04 
Sinn 2008 20 1.28 – 8.33 0.96 – 1.04 
Dapoigny 2012 26 0.57 – 1.23 0.96 – 1.04 
Ducrotte 2012 106 1.49 – 2.08 0.12 – 71.49 
Guglielmetti 2011 62 1.33 – 2.50 0.96 – 3.06 
Enck 2009 150 1.07 – 1.27 0.96 – 1.04 
Kruis 2012 60 0.82 – 1.51 0.76 – 1.62 
Gade 1989 22 1.01 – 1.89 0.96 – 1.04 
Inflammatory Bowel Disease 
Kruis 1997 103 0.53 – 3.79 0.23 – 1.89 
Rembacken 1999 83 0.69 – 1.22 0.60 – 3.53 
Kruis 2004 327 0.73 – 1.58 0.82 – 1.45 
Sood 2009 147 0.90 – 2.13 0.00 – 0.52 
Tursi 2010 144 0.58 – 3.36 0.37 – 2.24 
Matthes 2010 88 0.58 – 4.42 0.67 – 1.78 
Prantera 2002 32 0.79 – 3.65 0.09 – 1.60 
Bousvaros 2005 75 0.77 – 4.40 0.33 – 2.00 
Marteau 2006 98 0.33 – 5.88 0.36 – 3.01 
Van Gossum 2007 70 0.34 – 5.85 0.65 – 1.23 
 
 
 
Risk-Benefit Analysis 
A wide variety of quantitative methods exist for risk-benefit analysis(60).  Since we have little information on 
utilities for IBS and IBD in the literature, and most of the existing data on efficacy and risk comes from the 
abovementioned large number of clinical trials, we chose to use the risk-benefit plane, a method that plots the 
joint distribution of both risk and benefits(61).  The primary advantage of this approach is that both risk and 
benefit are visualized simultaneously, rather than using a one-dimensional measure such as risk-benefit ratio.  
Furthermore, data with a large, heterogeneous distribution across both risk and benefit can be better modeled 
as a two-dimensional confidence region than two separate confidence intervals. 
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First, we constructed a dataset using all existing clinical trials that reported both efficacy and adverse drug 
events for both IBS(24-38) or IBD(40-49), as described in Figure 1 and Table 1.  We sampled across the 95% 
confidence intervals for each trial weighted by the size of the trial (larger trials had a larger share of sampling).  
When no adverse events were reported, we estimated the 95% confidence interval as a function of the number 
of subjects (3/N), as described previously.(62) Once the data set was complete, we simulated 5000 patients by 
sampling (with replacement) for 5000 iterations.  Next, since the distribution of this cross-trial sample could not 
be assumed to have bivariate normality, we used a recently developed geometry-based method to determine 
confidence regions in bivariate samples.  This method is more robust whether the distribution is normal or non-
normal(61), and utilizes the R package “distfree.cr.”  Finally, the confidence region was plotted using this 
package on a risk-benefit plane (RBP) to illustrate where the joint distribution of risk and benefit lies.    
 
The end result is a geometric shape that visualizes the joint distribution of risk and benefit.  So, when 
encountering a patient with IBS or IBD who asks about probiotics, there is a 95% chance, based on the dataset 
employed, that the patient’s experience will lie somewhere in that region.  The shape of the curve determines 
where the average patient may fall:  if the area of the curve is mostly above the “risk-benefit threshold” line, 
they have more benefit than risk; if the area of the curve is mostly below this line, they have more risk than 
benefit.  Importantly, this does not quantify the severity of risk – only the presence of risk, nor does it quantify 
the type of benefit – only the presence or absence of a clinical endpoint of some kind.  In the case of 
probiotics, the severity is often low (worse abdominal pain, for instance), so this must be taken into 
consideration when interpreting the results. 
 
 
RESULTS OF QUANTITATIVE RISK-BENEFIT ANALYSIS 
 
 
IBS 
 
Figure 2 depicts the RBP for all published trials of probiotics for IBS.  The mean risk-benefit (solid black circle) 
lies along the dotted line representing the risk-benefit threshold.  So, the average patient will have an equal 
balance of risk and benefit.  Overall, most of the area within the 95% confidence region (red line) lies below the 
risk-benefit line, so in a slim majority of patients, risk for any ADE will outweigh benefit. Most simulated risk 
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data was modeled along a normal distribution (since most trials did not report any ADEs at all), so the range of 
risk was much narrower than the range of efficacy, resulting in an ovoid confidence region.  
Figure 2 – Risk-Benefit Plane for Irritable Bowel Syndrome.  The log transformed relative risk of an ADE is 
plotted on the horizontal axis.  The log transformed relative efficacy (in terms of relative rate of improvement in 
symptoms) is plotted on the vertical axis.  Grey circles are individual sampled points.  The black circle is the 
mean of all sampled points.  The red line represents the approximated 95% confidence region.  The dotted line 
represents the threshold between a poor risk-benefit ratio (below line) and an advantageous risk-benefit ratio 
(above line).  
 
 
IBD 
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Figure 3 depicts the RBP for all included trials of probiotics in IBD.  The mean risk-benefit (solid black circle) 
lies well above the dotted line, as does the majority of the 95% confidence region (red line).  The confidence 
region is quite large for IBD, which occurs due to the wide heterogeneity in confidence intervals that formed the 
primary data source.  Thus, in a general sense, probiotics seem to confer more benefit than risk for a majority 
of hypothetical patients, but with such a large area for the confidence region, the average patient could expect 
almost any risk-benefit ratio.  There is noticeable heterogeneity of the confidence region (for instance, a “cloud” 
of simulated points in the high-risk, high-benefit range), but this should not be interpreted that any specific sub-
population exists.  The method employed simply samples from all existing confidence intervals, so if one of the 
10 IBD studies had a particular narrow confidence interval, simulated patients may appear to cluster in that 
region, but the confidence region’s shape will take this variation into account.  We did not perform sub-group 
analyses (CD vs. UC or active vs. inactive disease) due to the relative lack of high quality data on which to 
build a RBP for sub-groups.   
Figure 3 – Risk-Benefit Plane for Inflammatory Bowel Disease.  The log transformed relative risk of an 
ADE is plotted on the horizontal axis.  The log transformed relative efficacy (in terms of relative rate of 
maintenance of remission) is plotted on the vertical axis.  Grey circles are individual sampled points.  The black 
circle is the mean of all sampled points.  The red line represents the approximated 95% confidence region.  
The dotted line represents the threshold between a poor risk-benefit ratio (below line) and an advantageous 
risk-benefit ratio (above line).  
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DISCUSSION 
 
Overall, the joint assessment of risk and benefit for probiotic use in either IBS or IBD remain a significant 
challenge.  Risk tends to be low in most patients, but so does efficacy.  It is furthermore unknown what risks 
immunocompromised patients face when taking probiotics.  Existing data on ADEs are quite poor, and most 
trials do not adopt a systematic approach to detecting them. 
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When we queried the FAERS database, we found relatively few ADEs.  In fact, given the high utilization of 
probiotics in the general population, the rate of reporting is quite low, and many ADEs have no clear rational 
association with probiotics (arthralgia, injection site pain from other medications, etc).  There may be several 
reasons for this finding:  (1) patients may not report probiotics as a medication since they are often marketed 
as supplements, (2) our search algorithm did not detect all reported cases, or (3) ADEs for probiotics may be 
so mild that they are not reported with much consistency.  We suspect that patients not primed to report an 
ADE (as in a clinical trial) probably experience at worst minimal and vague symptoms. 
 
When we performed quantitative risk-benefit plane analysis for both IBS and IBD, we noted a wide range of 
possible risk-benefit ratios, indicating that our knowledge of risk in probiotics remains poor for both of these 
disorders.  This may be a function of the heterogeneity of organisms used across studies, but also the unique 
problem inherent to using live organisms as therapy for complex and heterogeneous digestive diseases.  In 
either case, a standardized approach to ADEs in future probiotics trials will be essential to inform future 
treatment decisions. 
 
In IBS, the majority of the confidence region straddles the risk-benefit threshold, and the mean risk-benefit ratio 
lies along the threshold.  This is likely due to the fact that probiotics have low efficacy, but also low likelihood of 
an ADE.  Since studies used in the analysis are quite broad, it is very difficult to make individual 
recommendations for specific patients and patient populations.  On balance, it is reasonable to advise a trial of 
probiotics for patients with IBS. 
 
In IBD, the confidence region is larger, owing to wider confidence intervals within and among studies.  This 
could be a result of more varied study design, but also due to the heterogeneity of patients with IBD and the 
higher percentage of patients reporting ADEs.  A majority of the confidence region lies above the risk-benefit 
threshold, and the mean risk-benefit ratio is well above this threshold as well.  On balance, probiotics may be 
helpful in maintaining (or even inducing) remission, but the overall breadth of the confidence region indicates 
that uncertainty is high, so further studies are certainly needed to more accurately quantify both risk and 
benefit.  Since we have virtually no understanding of the risk of probiotics in the immunocompromised, very 
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careful consideration should be given to this population, which represents most IBD patients.  It is simply 
unknown if there is a sub-population of IBD patients with substantial immunosuppressant-related risk.  In 
situations where efficacy is more convincingly established (pouchitis prophylaxis with VSL#3 in patients with a 
colectomy, for instance(63, 64)), this unknown risk may be worth it, but in immunosuppressed IBD patients in 
general, for whom the efficacy confidence interval is broad and marginally significant, the potential severity of 
risk may not be worth it. 
 
There are several limitations to our quantitative analysis.  First, studies were analyzed in bloc, and no sub-
analysis was performed based on severity of disease, type of IBD, type of probiotic, outcomes measured, or 
specific ADEs assessed.  Performing a more clear RBP analysis would require a larger number of 
homogenous studies, especially those assessing risk in a rigorous way.  This is a particular challenge in 
probiotic clinical trials, but which is essential if we wish to expand the evidence base.  Second, since several 
IBS studies did not report any ADEs at all, the risk sampling frequently used the normal distribution.  This 
would tend to narrow the risk axis of the confidence region.  Finally, we did not specify what type of ADE 
patients would have, or the severity of the ADE.  Since most ADEs from probiotics are mild and not potentially 
life threatening, risk may be overestimated when simply specifying the rate of ADEs but not quantifying 
severity.  It is likely that many patients would be willing to tolerate mild gastrointestinal upset and many of the 
other ADEs listed in Table 2.  As noted above, there may also be sub-populations of immunosuppressed 
patient who have a similar rate of ADEs, but they might be much more severe and concerning. 
 
One very challenging aspect of the assessment of ADEs in probiotics is the difficulty in separating disease 
course and drug effect.  For instance, most suspected ADEs are gastrointestinal side effects, yet probiotics are 
most often used to treat gastrointestinal diseases, many of which have a relapsing, sporadic course as part of 
their natural history.  Therefore, it can be quite difficult to assess whether a symptom is truly the effect of a 
drug or simply the effect of the disease being treated. 
 
We believe many of the challenges of risk-benefit analysis in probiotics could be overcome by focusing future 
research in three ways:  (1) standardize methods of assessing ADEs in patients taking probiotics, (2) limiting 
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the breadth of probiotic species studied, and (3) improving the overall methodological quality of trials involving 
probiotics by using Guidelines for Good Clinical Practice (published by FDA as well as the World Health 
Organization) as are used for pharmaceutical trials. 
 
 
CONCLUSIONS 
 
Overall, the risk of probiotic use is low, but unfortunately so are benefit for both IBS and IBD.  Given that many 
patients (and clinicians) are desperate for effective and safe interventions for these disorders, a trial of a 
probiotic remains a reasonable, and usually safe, practice for these diseases.  Quantitative risk-benefit 
analysis using a risk-benefit plane indicates a confidence region shifted towards a slightly unfavorable risk-
benefit in IBS, and a slightly favorable risk-benefit in IBD.  
 
The use of probiotics in the immunocompromised host (including those on immunosuppressants for IBD) has 
not been well studied.  Given the low likelihood of most probiotic preparations to confer a large clinical benefit 
to a patient, it may be wise to advise against them in this at-risk population until further safety research has 
been performed. 
 
The evidence base for probiotics can be dramatically improved by both intensifying basic research into the 
mechanisms of probiotic efficacy and ADEs and by focusing efforts into higher quality clinical research. 
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